Policies aimed at alleviating the growing problem of drug-resistant pathogens by restricting antimicrobial usage implicitly assume that resistance reduces the Darwinian ¢tness of pathogens in the absence of drugs. While ¢tness costs have been demonstrated for bacteria and viruses resistant to some chemotherapeutic agents, these costs are anticipated to decline during subsequent evolution. This has recently been observed in pathogens as diverse as HIVand Escherichia coli. Here we present evidence that these genetic adaptations to the costs of resistance can virtually preclude resistant lineages from reverting to sensitivity. We show that second site mutations which compensate for the substantial (14 and 18% per generation) ¢tness costs of streptomycin resistant (rpsL) mutations in E. coli create a genetic background in which streptomycin sensitive, rpsL alleles have a 4^30% per generation selective disadvantage relative to adapted, resistant strains. We also present evidence that similar compensatory mutations have been ¢xed in long-term streptomycin-resistant laboratory strains of E. coli and may account for the persistence of rpsL streptomycin resistance in populations maintained for more than 10 000 generations in the absence of the antibiotic. We discuss the public health implications of these and other experimental results that question whether the more prudent use of antimicrobial chemotherapy will lead to declines in the incidence of drug-resistant pathogenic microbes.
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I N T RO DUC T ION
Recent laboratory studies of microbes as diverse as HIV (Borman et al. 1996) and E. coli (Bouma & Lenski 1988; Lenski et al. 1994; Schrag & Perrot 1996) challenge a widespread view (Levy 1994; OTA 1995; WHO 1995) that the frequency of drug-resistant pathogens will decline if drug usage is reduced. This view implicitly assumes that resistant strains have a competitive disadvantage relative to sensitive strains in the absence of drugs. The above-cited studies demonstrate that even when pathogen resistance is associated with substantial ¢tness costs, subsequent pathogen evolution reduces these burdens without lowering the level of resistance. In at least one case, adaptations to the cost of an antibiotic-resistance encoding plasmid in E. coli resulted in resistant bacteria which were more ¢t than the plasmid-free parental strain even in the absence of the antibiotic (Bouma & Lenski 1988) . Furthermore, in at least two studies (Borman et al. 1996; Schrag & Perrot 1996) , this rapid adaptation to the cost of resistance occurred in the absence of drugs selecting for resistance.
Here, we present evidence that adaptations to costs of resistance, in addition to reducing the ¢tness costs of resistance, can create a genetic background that confers a selective disadvantage on sensitive alleles. Using rpsL strains of E. coli, we demonstrate that second site mutations which compensate for the ¢tness costs associated with resistance create a genetic background in which wild-type, streptomcyin-sensitive alleles (rpsL ) have a marked selective disadvantage. Stated another way, these compensatory mutations establish an`adaptive valley' (Wright 1932; Dobzhansky 1951 ) which virtually precludes the evolved, resistant lineages from reverting to drug sensitivity. We present retrospective evidence which suggests that compensatory evolution and a resulting`adaptive valley' may have contributed to the stability of streptomycin resistance in long-term, antibiotic-free laboratory cultures of E. coli B. We conclude with a brief discussion of the clinical and public health implications of these and related experimental results.
. M ET HOD S (a) Strains
Our wild-type, streptomycin-sensitive strain was E. coli CAB281, an E. coli K1/K12 chimera (wM1002 in Bloch & Rode (1996) ). Spontaneous streptomycin-resistant mutants of this strain, STR1 and STR2, di¡ered from the wild-type by single base substitutions at codon 42 of the rpsL gene resulting in threonine and aspargine, respectively, instead of the wildtype lysine. STR11 and STR12 were clones of the parental strain STR1, which were maintained independently in serial transfer culture in the absence of streptomycin for 180 generations (as described in Schrag & Perrot (1996) ). Similarly, STR21 and STR22 were 180-generation evolved strains derived independently from STR2 . The rpsL sequence in all four evolved strains did not di¡er from the parental sequence (Schrag & Perrot 1996) . Our strain of E. coli B was a subclone of strain Bc251 (T6 r , Str r ) (Lederberg 1966 ) donated by S. Lederberg. REL4548 (Lenski & Travisano 1994 ), a 10 000-generation evolved descendant of this E. coli B strain, was donated by R. Lenski.
(b) P1 phage-mediated transduction P1 transduction was performed using P1vir, donated by D. Thaler. Phage were grown on an Str s donor strain, E. coli K12 CAG18556 (Singer et al. 1989 ) provided by C. Gross, which had a kanamycin-resistance marker (Kan r ) 1min from rpsL. Lysate preparation and P1 transduction followed Miller (Miller 1972 transductants in 50 ml £asks containing 10 ml of culture medium. Competitions were maintained for at least 33 generations of growth, by transferring daily 0.025 ml of stationary phase culture to fresh glucose-limited (500 mg ml 71 ) Davis minimal medium (Carlton & Brown 1981) supplemented with MgSO 4 and thiamine in excess and nicotinic acid to a ¢nal concentration of 10 mg ml
71
. In cases where the streptomycin-sensitive transductants had a strong selective disadvantage, the initial ratio of sensitive to resistant strains was 100:1, rather than 1:1, to increase the number of generations over which changes in the relative frequency of the Str s strain could be measured. The selection coe¤cient of a given strain was then estimated by the regression coe¤cient of the natural log of the ratio of sensitive to resistant strains plotted against time (generations of competition) (Lenski 1991) . Relative ¢tness per bacterial generation was calculated as one minus the selection coe¤cient (Lenski 1991) .
For each Str s transductant, a single pairwise competition was performed against each of two independent Str r transductants of the same recipient. Because the ¢tness of independent Kan r Str r transductants relative to their unmanipulated Str r recipient was not found to vary signi¢cantly (unpublished results), a single regression was ¢tted through the points from both pairwise competitions instead of calculating a regression coe¤cient for each separately. Reported standard errors and p values are calculated for the regression coe¤cient.
R E SU LT S
Using P1-mediated transduction, we replaced the rpsL alleles in a collection of Str r strains of E. coli CAB281with the wild-type, sensitive allele. Two strains from this collection (STR1 and STR2) were newly isolated Str r mutants with 14 and 19% per generation ¢tness disadvantages relative to the wild-type strain (Schrag & Perrot1996) .The remaining strains, evolved descendants of these two mutants, carried second-site mutations which compensated for these ¢tness disadvantages without reducing the resistance to streptomycin (Schrag & Perrot 1996) . The wild-type rpsL allele introduced into these strains came from a Str s E. coli K12 donor strain carrying a Kan r marker 1min from the rpsL gene. In the unevolved recipient strains, STR1 and STR2, we obtained a modest frequency of Kan r Str s co-transductants, as would be expected from the 1min map distance between these two genes (table 1). In one of the evolved strains, STR21, we obtained a similar frequency of co-transductants. In the evolved strains STR12 and STR22, however, the rate of co-transduction of the Kan r and Str s alleles was substantially lower, and in the last of these evolved strains (STR11), we failed to obtain any Kan r Str s co-transductants after screening nearly 4000 Kan r colonies. This suggests that the Str s allele in evolved genetic backgrounds reduced bacteria viability.
To test directly whether a ¢tness cost was associated withwild-type, rpsL alleles in strainsbearing mutations compensating for the costs of resistance, we measured the ¢tness of wild-type alleles relative to resistant alleles in Schrag & Perrot (1996) , except the E. coli B strain which is described by S. Lederberg (1966) As anticipated from our original observations (Schrag & Perrot 1996) , the Str s allele had a marked advantage over Str r alleles in the unevolved genetic background (¢gure 1a). Moreover, the ¢tness costs associated with these resistance alleles in transductants were similar to the 14% and 19% per generation ¢tness costs estimated in previous competition experiments between wild-type and resistant mutant strains (Schrag & Perrot 1996) .
In contrast to this strong advantage of the Str s allele in the unevolved genetic background, in evolved strains carrying second-site compensatory mutations the Str s allele had a signi¢cant ¢tness disadvantage relative to the resistant alleles (¢gure 1b). In the evolved genetic background of STR21, the ¢tness disadvantage of the Str s allele was modest, 3% per generation. In the background of the other two evolved strains, STR12 and STR22, the ¢tness disadvantage of Str s was much greater, ranging between 20 and 25% per generation. The di¡erence between the disadvantages of the Str s allele in two backgrounds (STR21 and STR22) evolved from the same parental strain (STR2) is consistent with previous evidence (Schrag & Perrot 1996) suggesting that more than one second site mutation can compensate for the ¢t-ness costs of a given Str r , rpsL allele. If the present observations are general, then rpsL alleles should be associated with a ¢tness cost in laboratory rpsL strains that have been maintained for extensive periods, even if these strains have been maintained in the complete absence of streptomycin. We tested this prediction using a laboratory strain of E. coli B (Lederberg 1966 ) which was resistant to streptomycin when ¢rst received in our laboratory in 1970, and which has been used most recently by R. Lenski and colleagues to initiate a series of long-term experimental evolutionary studies Lenski & Travisano 1994; Travisano et al. 1995; Elena et al. 1996; Travisano & Lenski 1996) . In these experiments, this strain was allowed to adapt over the course of 10 000 generations to serial transfer culture in streptomycinfree, glucose-limited medium. Despite signi¢cant changes in cell size, ¢tness, and physiology over this period Lenski & Travisano 1994) , we found using standard DNA ampli¢cation and sequencing methods (described in Schrag & Perrot (1996) ) that the rpsL sequences of the 10 000 generation strain and its parental E. coli B strain are identical. In place of the wild-type lysine at codon 42, both strains carry a point mutation resulting in ACA that codes for threonine.
Furthermore, when we replaced this rpsL allele in the unevolved, parental strain by the wild-type, Str s allele, ¢ve Kan r Str s transductants had an average ¢tness cost of 26% (range 20.3^30%) per generation relative to Kan r Str r transductants. This provides evidence that mutations compensating for the ¢tness costs of streptomycin resistance arose in this strain prior to the initiation of long-term evolution studies by Lenski et al. However, unlike 
. DI S C U S S ION
Mutations which decreased the ¢tness costs of chromosomal streptomycin-resistance in E. coli also created a genetic background in which streptomycin-sensitive revertants have a strong selective disadvantage. In the context of the Wrightian adaptive landscape metaphor (Wright 1932; Dobzhansky 1951) , the genetic changes that compensate for the cost of resistance establish a valley that separates the adaptive peaks of drug sensitivity and ¢tness-compensated resistance (¢gure 2). Not only are at least two mutations required for an evolved resistant strain to become a high-¢tness sensitive strain, individually each of these mutations reduces the ¢tness of that strain. As a result, it would be very di¤cult for an evolved resistant lineage to become sensitive, even in the absence of the drug. The e¡ect of the Str s allele in the evolved genetic background. Estimates of selection coe¤cients, shown in parentheses below the strain names, are based on at least two pairwise competitions per strain. These estimates were calculated by linear regression (shown by lines on the graphs) as described in ½2. Standard errors were based on the regression and all p values of the regressions were less than 0.00015.
From a clinical and public health perspective, these results point to another potentially general reason why reductions in antimicrobial usage may not lead to rapid declines in the incidence of resistant pathogens. Compensation for the ¢tness costs of resistance has been shown to occur both in the presence and in the absence of drug selection (Bouma & Lenski 1988; Lenski et al. 1994; Borman et al. 1996; Schrag & Perrot 1996) . In the latter case, mathematical models suggest that compensatory evolution, rather than reversion to sensitivity, is expected to occur as long as the rate of compensatory mutations exceeds that of reversion to sensitivity, and only a fraction of the population is transferred to colonize a new host (Levin et al. 1997) .
Our observations that such compensation confers a selective disadvantage on sensitive revertants are speci¢c to chromosomal streptomycin resistance in E. coli. Furthermore, this may be a speci¢c feature of ribosomal resistance mutations due to the complexity of ribosomal protein interactions, and further studies of other target mutations observed in clinical isolates (e.g. alterations of RNA polymerase, or gyrase) are required to establish the generality of our observations. Nonetheless, evidence from other studies suggests that analogous adaptive valleys between sensitive and adapted, resistant peaks may exist for other cases of resistance. In the case of plasmidborne resistance (Bouma & Lenski 1988; Lenski et al. 1994) , a tetracycline resistance-encoding plasmid which initially reduced the ¢tness of host bacteria in the absence of tetracycline, actually augmented bacterial ¢tness after 500 generations of culture in association with the bacterial host. Adaptive valleys of the sort observed here are also likely to be present in cases where resistance to clinical levels of chemotherapeutic agents is achieved through the sequential substitution of multiple mutations, each of which is favoured in the presence of the drug (e.g. AZT resistance (Larder & Kemp 1989; Kellam et al. 1994) ; protease inhibitor resistance (Borman et al. 1996) ). In these cases, reversion to sensitivity requires the substitution of multiple mutations. It is likely, and there is suggestive evidence in a study of HIVresistance to a protease inhibitor (Borman et al. 1996) , that reversions at these loci will not be selected because they do not improve, and often reduce pathogen ¢tness.
While this evidence comes from in vitro systems, epidemiological studies in the case of HIV also suggest that resistant strains will not wane rapidly with reduced drug use. An AZT-resistant HIV strain transmitted by heterosexual contact has persisted as the dominant virus population in the recipient host who was never treated with AZT, showing that AZT-resistant strains persist for longer than anticipated in the absence of drug treatment (Conlon et al. 1994) . Furthermore, AZT-resistant strains have been slow to wane in patients who have discontinued AZT-treatment (Boucher et al. 1993) .
Despite this, we do not believe these observations should be construed as arguments for the futility of controlling resistance by reduced and more prudent drug use. While the mechanisms discussed here will substantially retard the rate at which any given lineage of resistant pathogens declines even in the complete absence of drug usage, they need not preclude a return to drug sensitivity. Population models have shown that as long as populations of pathogenic microbes are polymorphic and include sensitive as well as resistant lineages, and as long as these sensitive strains have some competitive advantage over resistant strains, reductions in drug usage will increase the frequency of the sensitive strains and the likelihood of these lineages replacing resistant lineages (Levin et al. 1997) . Furthermore, the rate and extent to which pathogens adapt, by compensatory mutations and other mechanisms, to an environment where drugs are prevalent is expected to decrease with decreased drug usage. Increasing the number of in vivo and epidemiological studies, where spatial refuges and migration of drug-sensitive pathogens in particular might play important roles, will be particularly important in understanding how to control drug resistance within pathogen populations.
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